Back to discover

Protein / target

Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN

Encoded byPTENP60484Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
9
Research papers

Protein at a glance

Biological role

Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase

Strongest disease association

Glioma

Via encoding gene PTEN · Genetic literature evidence · score 0.81

Research activity

Emerging research

9 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins.

View complete UniProt function annotation

Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5-trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664, PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5-tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival (PubMed:31492966, PubMed:37279284). The unphosphorylated form cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation (PubMed:22279049). Required for growth factor-induced epithelial cell migration; growth factor stimulation induces PTEN phosphorylation which changes its binding preference from the p85 regulatory subunit of the PI3K kinase complex to DLC1 and results in translocation of the PTEN-DLC1 complex to the posterior of migrating cells to promote RHOA activation (PubMed:26166433). Meanwhile, TNS3 switches binding preference from DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge of migrating cells to activate RAC1 activation (PubMed:26166433). Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). Involved in the regulation of synaptic function in excitatory hippocampal synapses. Recruited to the postsynaptic membrane upon NMDA receptor activation, is required for the modulation of synaptic activity during plasticity. Enhancement of lipid phosphatase activity is able to drive depression of AMPA receptor-mediated synaptic responses, activity required for NMDA receptor-dependent long-term depression (LTD) (By similarity). May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability (PubMed:10468583, PubMed:18716620)

Subcellular location

CytoplasmNucleusNucleus, PML bodyCell projection, dendritic spinePostsynaptic densitySecreted
Domains and Gene Ontology detail (93)

Domains & features

Phosphatase tensin-typeC2 tensin-type

Gene Ontology

  • Capical plasma membrane
  • Ccell projection
  • Ccytoplasm
  • Ccytoplasmic side of plasma membrane
  • Ccytosol
  • Cdendritic spine
  • Cextracellular region
  • Cmyelin sheath adaxonal region
  • Cneuron projection
  • Cnucleoplasm
  • Cnucleus
  • Cplasma membrane

403 aa · 47 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationUniProt · GOCell proliferation & survivalUniProt · GOExcitatory neurotransmissionGOCell-cycle regulationGOKinase signallingGOMotor controlGO
View supporting evidence

Cell migration

  • ·Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine…
  • ·cell migration
  • ·cell motility
  • ·negative regulation of cell migration

Cell proliferation & survival

  • ·Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine…
  • ·negative regulation of cell population proliferation
  • ·positive regulation of cell population proliferation

Excitatory neurotransmission

  • ·negative regulation of excitatory postsynaptic potential
  • ·positive regulation of excitatory postsynaptic potential

Cell-cycle regulation

  • ·negative regulation of G1/S transition of mitotic cell cycle

Kinase signalling

  • ·negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
  • ·phosphatidylinositol 3-kinase/protein kinase B signal transduction
  • ·regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction

Motor control

  • ·locomotor rhythm
  • ·locomotory behavior

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PTEN

Gene-level evidence surfaced through the gene PTEN that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Glioma
0.91Well supported

Genetic evidence dominant · Open Targets 0.72

Melanoma
0.84Well supported

Genetic literature evidence dominant · Open Targets 0.71

Squamous Cell Carcinoma of Head and Neck
0.80Well supported

Genetic literature evidence dominant · Open Targets 0.70

View evidence synthesis (3)
GliomaWell supported
0.91
agreement 0.821.00
Genetic43%Pathway18%Somatic mutation18%Animal model13%Literature9%Genetic literaturedup

Open Targets aggregate 0.72 · 5 independent evidence families · 1 not counted as duplicate

MelanomaWell supported
0.84
agreement 0.720.96
Genetic literature48%Somatic mutation41%Literature12%

Open Targets aggregate 0.71 · 3 independent evidence families

Squamous Cell Carcinoma of Head and NeckWell supported
0.80
agreement 0.680.92
Genetic literature58%Somatic mutation30%Literature12%Geneticdup

Open Targets aggregate 0.70 · 3 independent evidence families · 1 not counted as duplicate

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Glioma0.72
Melanoma0.71
Squamous Cell Carcinoma of Head and Neck0.70

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
SM · Structure with LigandAB · UniProt loc high confAB · GO CC high confPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

regulation of transcription factor activityToxCastregulation of catalytic activityToxCastdrug toxicityClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

9 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Mellinghoff IK · The New England journal of medicine · 2005

Schmid P · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020

Chen L · Signal transduction and targeted therapy · 2020

Recent

Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis.

Chaudagar K · Clinical cancer research : an official journal of the American Association for Cancer Research · 2023

Regulating tumor suppressor genes: post-translational modifications.

Chen L · Signal transduction and targeted therapy · 2020

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Schmid P · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Mellinghoff IK · The New England journal of medicine · 2005

Europe PMC papers linked directly to this protein.